This study aimed to explore the improvement of hip replacement combined with
alendronate sodium on the condition of patients with osteoporotic
femoral neck fracture and factors affecting the efficacy of patients. In total, 140 patients with
femoral neck fracture from July 2015 to October 2017 in the Affiliated Xuzhou Hospital of Jiangsu University were collected. Of these, 61 patients were treated with hip replacement as the control group and 79 patients were treated with
alendronate sodium as the observation group on the basis of the control group. ELISA was used to detect levels of carboxy-terminal opeptide of
type I collagen (CTX-I) and bone
alkaline phosphatase (BALP) in serum of patients before and
after treatment. Harris score was used to compare the clinical efficacy of patients
after treatment. Changes in the expression of CTX-I and BALP before and
after treatment were compared between the two groups, and the correlation between CTX-I and BALP levels and Harris score was analyzed. According to the clinical efficacy of patients, the two groups were divided into the significant effect group and poor effect group. Risk factors affecting the efficacy of patients were analyzed, and the ROC of subjects with risk factors was drawn.
After treatment, the expression of BALP in serum increased significantly compared with that before treatment, and the expression of CTX-I decreased significantly.
After treatment, the expression of BALP in serum in the observation group was significantly higher than that in the control group (P<0.05). Multivariate analysis revealed that age, time of operation, CTX-I
after treatment and BALP
after treatment were independent risk factors affecting the efficacy of patients. In conclusion, hip replacement combined with
alendronate sodium can effectively improve the clinical efficacy of patients, and age, time of operation, CTX-I
after treatment and BALP
after treatment are found to be independent risk factors affecting the postoperative efficacy of patients.